Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Acquired by Koa Wealth Management LLC

Koa Wealth Management LLC increased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 1.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 74,483 shares of the biopharmaceutical company’s stock after acquiring an additional 915 shares during the period. Halozyme Therapeutics makes up about 3.3% of Koa Wealth Management LLC’s holdings, making the stock its 8th largest holding. Koa Wealth Management LLC owned about 0.06% of Halozyme Therapeutics worth $4,263,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Congress Asset Management Co. increased its position in shares of Halozyme Therapeutics by 446.5% in the 3rd quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock valued at $139,298,000 after purchasing an additional 1,988,238 shares during the last quarter. Handelsbanken Fonder AB raised its stake in Halozyme Therapeutics by 76.9% in the third quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock valued at $112,715,000 after buying an additional 856,200 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Halozyme Therapeutics by 12.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock worth $99,363,000 after buying an additional 209,530 shares during the last quarter. Epoch Investment Partners Inc. boosted its position in shares of Halozyme Therapeutics by 23.3% during the 1st quarter. Epoch Investment Partners Inc. now owns 1,433,612 shares of the biopharmaceutical company’s stock worth $58,319,000 after acquiring an additional 270,579 shares in the last quarter. Finally, American Century Companies Inc. increased its holdings in shares of Halozyme Therapeutics by 9.7% in the 2nd quarter. American Century Companies Inc. now owns 821,266 shares of the biopharmaceutical company’s stock valued at $43,002,000 after acquiring an additional 72,544 shares during the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on HALO. JPMorgan Chase & Co. downgraded Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their price target for the company from $52.00 to $57.00 in a report on Thursday, September 19th. Benchmark reaffirmed a “buy” rating and issued a $60.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. TD Cowen boosted their price target on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Piper Sandler upped their price objective on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the company a “neutral” rating in a research note on Monday, November 4th. Finally, JMP Securities lifted their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $61.11.

Insider Buying and Selling at Halozyme Therapeutics

In other news, CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction on Wednesday, October 9th. The shares were sold at an average price of $52.58, for a total value of $525,800.00. Following the completion of the sale, the chief executive officer now owns 676,744 shares in the company, valued at approximately $35,583,199.52. This trade represents a 1.46 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders have sold 70,000 shares of company stock worth $4,042,500. 2.40% of the stock is currently owned by insiders.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $45.65 on Friday. The stock’s 50-day moving average price is $56.04 and its 200 day moving average price is $53.27. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The stock has a market capitalization of $5.81 billion, a PE ratio of 15.12, a price-to-earnings-growth ratio of 0.54 and a beta of 1.29. Halozyme Therapeutics, Inc. has a 52-week low of $33.15 and a 52-week high of $65.53.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.